GlycanLink, located in Shanghai Zhangjiang Pharmaceutical Valley, Shanghai, is a biopharmaceutical company focusing on site-specific conjugation technologies for ADCs. Founded in 2021 by Dr. Huang Wei, a researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, GlycanLink has mastered a number of site-specific conjugation technologies for ADCs with independent intellectual property rights.

GlycanLink is committed to establishing a worldwide first-class site-specific conjugated ADC service platform at home and abroad. With cooperative development and technology licensing as its core operating models, GlycanLink provides R&D services to clients, continuously optimizes processes, elevates product quality and R&D value, and enables the development of next-generation ADC. At the same time, we attach importance to the development of pipelines with our intellectual property rights. We are currently carrying out multi-pipeline promotion, including hot targets and emerging targets.